Webinar on June 18th: HIV Deja Vu? Optimizing combination therapies for COVID-19

With a vaccine likely a year or longer away, there is urgency around determining the right therapeutic at the right dose to fight COVID-19. Results from clinical trials of monotherapies have been a mixed bag to date, and there has not been a clear leading and proven therapeutic in this race. Monotherapy treatment must be initiated very early in viral infection and be quite potent. A combination therapy where different steps of the SARS-CoV-2 life cycle are modestly impacted may be a better strategy. A cocktail of antiviral drugs or a mix of antivirals and anti-inflammatory medicines could be more effective against COVID-19 than monotherapies, which is what we learned with HIV. We propose that combinations of drugs that act at multiple sites in the viral life cycle should be evaluated in randomized controlled clinical trials.


In this webinar, experts in drug development in a pandemic setting will discuss:

  • – Combination therapies that act at multiple sites on the viral life cycle
  • – Viral-kinetic modeling to understand the disease course and predict therapy outcomes
  • – Learnings to date from a combination therapy trial with hydroxychloroquine and lopinavir/ritonavir
  • – Drug-drug-interaction considerations
  • – Efficient new strategies for clinical trials
Date: June 18, 2020
Time: 1:00 pm ET
Duration: 1 hour
Edward Mills, PhD, Vice President of Real World Evidence and Senior Principal Scientist at Cytel
Michael Dodds, PhD, Executive Director Integrated Drug Development at Certara
Suzanne Minton, PhD, Director of Content Strategy at Certara
Rajesh Krishna, PhD, Senior Director, Clinical Pharmacology at Certara

Leave a Reply

Your email address will not be published. Required fields are marked *